School of Medicine and Medical Science, UCD Conway Institute, University College Dublin, Dublin, Ireland.
School of Biomedical and Biomolecular Science, UCD Conway Institute, University College Dublin, Dublin, Ireland.
J Thromb Haemost. 2015 Jun;13 Suppl 1:S323-31. doi: 10.1111/jth.12943.
Antiplatelet agents represent the mainstay of acute coronary syndrome (ACS) therapy to prevent ischemic events and to improve safety in patients undergoing percutaneous coronary intervention. However, despite the availability of several drugs and the use of dual antiplatelet therapy, the pharmacological response is highly variable with a subset of patients continuing to experience recurrent thrombotic events, revealing a wide variability in platelet response to antiplatelet drugs. Several factors may explain this, including genetic variation and environmental factors. Here we look at the application of proteomic analysis, an approach that provides an integrated readout of these diverse influences.
抗血小板药物是急性冠状动脉综合征（ACS）治疗的主要手段，可预防缺血事件，并提高经皮冠状动脉介入治疗患者的安全性。然而，尽管有多种药物可供使用，并采用双联抗血小板治疗，但药物反应的个体差异很大，一部分患者仍会发生复发性血栓事件，表明血小板对抗血小板药物的反应存在广泛的变异性。有几个因素可以解释这一点，包括遗传变异和环境因素。在这里，我们探讨了蛋白质组学分析的应用，这种方法可以综合分析这些不同的影响因素。
